24
Participants
Start Date
July 31, 2006
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Imatinib
Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
H. Lee Moffitt Cancer Center, Tampa
University of Chicago, Chicago
MD Anderson Cancer Center, Houston
University of Colorado at Denver Health Sciences Center, Denver
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Novartis
INDUSTRY
Dana-Farber Cancer Institute
OTHER